Abstract
Overview
Introduction
Rheumatoid arthritis is a debilitating and life-long disease that is estimated
to affect approximately 5 million people in the seven major markets. The
launch of anti-TNF products over six years ago and more recent novel target
biologic therapies have added significantly to the treatment options, but have
resulted in a crowded market for moderate to severe patients.
Scope
- Disease overview including epidemiology, physician estimated diagnosis
rates and severity split, including mild to severe and early active disease
- Breakdown of treatment trends in the following markets: US, Japan, France,
Germany, Italy, Spain and the UK
- PCPs and rheumatologists surveyed to capture the treatment of the ranging
severities with traditional NSAIDs, COX-2s, traditional and biologic DMARDs
- Comparative brand assessment on the key attributes of Enbrel, Remicade,
Humira, Orencia, Rituxan/MabThera, Kineret and methotrexate
Highlights
Inclusion of relevant early active RA patients in clinical studies will assist
timely approval in this indication, increasing the patient base for any RA
product. Definition of 'early' RA requires a balance between the physician
ideal of less than 12 months, giving the best patient response, and capturing
a substantial proportion of the market.
Physicians estimate nine months from disease onset to diagnosis. 25% of RA
patients are estimated to be severe, and take an average of four months before
the first DMARD is prescribed, being methotrexate in 60% of physicians. It can
be 18-23 months before a severe patient is likely to use a biologic.
Anti-TNF therapy is expected to continue to dominate the first-line biologic
use. Humira is perceived to be the most effective in terms of disease
modification, indicating a very positive future status for this brand, but
Remicade and Kineret could lose the brand battle if perception on certain
attributes doesn't improve.
Reasons to Purchase
- Use estimated treatment class patient numbers to forecast product use
across the seven major markets
- Exploit physician perceptions of key brands on clinical and market
attributes, to differentiate products in the crowded rheumatoid arthritis
market
- Understand differential treatment in niche populations such as severe and
early active rheumatoid arthritis
| 
View Cart
